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Arginase metabolizes the semi-essential amino acid L-arginine to L-ornithine and urea.
There are two distinct isoforms of arginase, arginase I and II, which are encoded by separate
genes and display differences in tissue distribution, subcellular localization, and molecular
regulation. Blood vessels express both arginase I and II but their distribution appears to
be cell-, vessel-, and species-specific. Both isoforms of arginase are induced by numerous
pathologic stimuli and contribute to vascular cell dysfunction and vessel wall remodeling
in several diseases. Clinical and experimental studies have documented increases in the
expression and/or activity of arginase I or II in blood vessels following arterial injury and
in pulmonary and arterial hypertension, aging, and atherosclerosis. Significantly, pharma-
cological inhibition or genetic ablation of arginase in animals ameliorates abnormalities in
vascular cells and normalizes blood vessel architecture and function in all of these patho-
logical states. The detrimental effect of arginase in vascular remodeling is attributable to
its ability to stimulate vascular smooth muscle cell and endothelial cell proliferation, and
collagen deposition by promoting the synthesis of polyamines and l-proline, respectively. In
addition, arginase adversely impacts arterial remodeling by directing macrophages toward
an inflammatory phenotype. Moreover, the proliferative, fibrotic, and inflammatory actions
of arginase in the vasculature are further amplified by its capacity to inhibit nitric oxide (NO)
synthesis by competing with NO synthase for substrate, L-arginine. Pharmacologic or mol-
ecular approaches targeting specific isoforms of arginase represent a promising strategy
in treating obstructive fibroproliferative vascular disease.
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INTRODUCTION
Arterial remodeling is characterized by alterations in the struc-
ture and function of the vascular wall in response to specific
pathophysiologic stimuli. Although vascular remodeling naturally
occurs in response to aging, it also arises in response to injury and
disease. The remodeling response is characterized by alterations
of one or all three layers of the blood vessel wall: the adventi-
tia, media, and intima. It is driven by numerous complex and
interrelated pathological processes that influence both the cellular
and non-cellular components of the vascular wall (Orford et al.,
2000; Jeffrey and Wanstall, 2001; Dzau et al., 2002; van Varik et al.,
2012). The proliferation of cells within the vessel wall is a major
contributor to arterial remodeling. The proliferation of vascu-
lar smooth muscle cells (SMCs) and/or endothelial cells (ECs)
leads to intimal thickening, hyperplasia, or hypertrophy of SMCs
results in medial thickening, and fibroblast proliferation causes
adventitial expansion. In addition, the recruitment of inflam-
matory cells from the circulation alters the cellular composition
and mass within the vessel wall. These cellular modifications are
often accompanied by increased deposition of extracellular matrix
material, such as collagen and fibronectin, as well as the frag-
mentation and degradation of elastin which adversely affects the
biomechanical properties of blood vessels. Furthermore, changes
in cell phenotype supports vascular remodeling. The dedifferenti-
ation of vascular SMCs from a contractile to a synthetic phenotype
that occurs in response to arterial injury aids vascular remodeling
by augmenting the secretion of collagen and other extracellular
matrix proteins (Owens et al., 2004). Synthetic SMCs also gener-
ate matrix metalloproteinases that facilitates SMC migration from
the media to the intima by detaching these cells from the basement
membrane and extracellular matrix (Bendeck et al., 1996). More-
over, the phenotype of ECs plays a pivotal role in the remodeling
response. In response to blood flow and shear stress, ECs release
a myriad of humoral factors, including the gas nitric oxide (NO),
which maintains vascular SMCs in a quiescent non-proliferative
and differentiated non-secretory state (Bonetti et al., 2003; Ver-
sari et al., 2007). However, EC function decreases with age and
disease resulting in diminished NO synthesis and enhanced pro-
duction of cytokines and chemokines that triggers the recruitment
and infiltration of immune cells into the vessel wall. Moreover,
dysfunctional ECs generate various growth factors that stimu-
late SMCs to proliferate, dedifferentiate, and synthesize collagen.
Finally, leukocytes that traffic into the vessel wall exhibit distinct
phenotypes that can influence the structure of the vessel wall by
enhancing or resolving vascular inflammation.
Arterial remodeling is a salient feature of aging and plays a
fundamental role in the development of several vascular dis-
orders, including atherosclerosis, restenosis after percutaneous
coronary intervention, post-transplant vasculopathy, systemic and
pulmonary hypertension, and aortic aneurysm and dissection
(Ross, 1999; Jeffrey and Wanstall, 2001; Dzau et al., 2002; Schiffrin,
2012). The targeting of specific pathophysiological pathways that
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contribute to arterial remodeling offers a potential approach for
therapeutic intervention. Despite extensive investigation, the dis-
covery and translation of potential targets of vascular remodeling
to the clinic has met with limited success. However, studies in the
past few years have identified arginase as a promising therapeutic
target that underlies many of the pathophysiological processes that
contribute to arterial remodeling (Durante et al., 2001; Wei et al.,
2001; Li et al., 2002; Chicoine et al., 2004; Ryoo et al., 2008; Kim
et al., 2009; Chen et al., 2012; Ming et al., 2012; Cho et al., 2013).
This article will review the mechanisms by which arginase pro-
motes aberrant vascular remodeling in arterial injury, pulmonary
and systemic hypertension, aging, and atherosclerosis, focusing
on the cellular actions of enzyme. In addition, it will highlight
arginase as a novel therapeutic modality in the prevention and
treatment of occlusive vascular proliferative disease.
L-ARGININE METABOLISM BY VASCULAR CELLS
l-Arginine is a semi-essential amino acid that is involved in
numerous physiological processes. It is a necessary precursor for
protein and creatinine biosynthesis and plays a role in modulating
nitrogen balance. In addition, l-arginine is metabolized by vascu-
lar cells to a number of important regulatory molecules (Figure 1).
Studies in the late 1980s, discovered that l-arginine is oxidized to
NO and l-citrulline by nitric oxide synthase (NOS) (Hibbs et al.,
1988; Palmer et al., 1988). l-Citrulline is subsequently recycled
back to l-arginine by the successive actions of argininosuccinate
synthetase and argininosuccinate lyase (Hecker et al., 1990). There
are three distinct isoforms of NOS; neuronal NOS (nNOS or NOS-
1), endothelial NOS (eNOS or NOS-3), and inducible NOS (iNOS
or NOS-2) (Forstermann and Sessa, 2012). These isozymes display
differences in tissue distribution, intracellular localization, molec-
ular regulation, enzyme kinetics, and calcium-dependency. Aside
from serving as a substrate, l-arginine plays an important struc-
tural and functional role by facilitating the intracellular assembly
of the dimeric form of NOS and the proper coupling between
the oxidative and reductive domains of the enzyme (Baek et al.,
1993; Forstermann and Munzel, 2006). The release of NO by vas-
cular cells plays an important homeostatic role in the circulation
by inhibiting vascular tone, platelet aggregation, leukocyte adhe-
sion and infiltration into the vessel wall, and the proliferation and
migration of vascular SMCs (see Durante, 2001; Forstermann and
Sessa, 2012).
Studies in the 1990s revealed that vascular cells also express
the enzyme arginase that catalyzes the hydrolysis of l-arginine to
l-ornithine and urea (Buga et al., 1996; Durante et al., 1997).
There are two distinct isoforms of arginase, arginase I and II,
which are encoded by separate genes and share approximately
60% amino acid sequence homology (Dizikes et al., 1986; Vockley
et al., 1996). These isozymes exhibit differential tissue distribu-
tion, subcellular localization, and molecular regulation (Jenkinson
et al., 1996). Arginase I is a cytosolic enzyme that is abundantly
expressed in the liver and plays an essential role in hepatic urea
cycle. In contrast, arginase II is a mitochondrial enzyme that is
widely expressed outside the liver, most prominently in the kidney
and prostate (Vockley et al., 1996; Morris et al., 1997). Notably,
arginase I germline knockout mice die shortly after birth due to
severe hyperammonemia whereas arginase II-deficient mice are
viable (Shi et al., 2001; Iyer et al., 2002). The arginase prod-
uct l-ornithine is further metabolized by the cytosolic enzyme
ornithine decarboxylase to the polyamine putrescine which forms
the successive polyamines, spermine, and spermidine (Tabor and
Tabor, 1984). SMC and EC proliferation is preceded by increases
in polyamine synthesis and inhibition of polyamine formation
abolishes cell growth (Morrison and Seidel, 1995; Durante et al.,
1996b, 1998). l-Ornithine is also catabolized by the mitochondr-
ial enzyme ornithine aminotransferase to pyrroline-5-carboxylate,
which is further metabolized to l-proline by the enzyme pyrroline
5-carboxylate reductase. l-Proline is required for the synthesis of
many structural proteins, including collagen (Durante et al., 2000,
2001). Finally, l-arginine may also be metabolized by the enzyme
arginine decarboxylase to agmatine, which elicits anti-proliferative
effects (Regunathan et al., 1996). However, these latter findings
need further corroboration.
REGULATION OF ARGINASE EXPRESSION IN VASCULAR
CELLS
Recent studies have documented the presence of arginase in a mul-
titude of blood vessels, including the aorta, carotid and pulmonary
artery, retinal arteries, coronary arteries, and gracilis muscle arte-
rioles (see Durante et al., 2007; Morris, 2009; Elms et al., 2013).
FIGURE 1 | Regulation of L-arginine metabolism by vascular cells. NO, nitric oxide; NOS, nitric oxide synthase; ASS, argininosuccinate synthetase; ASL,
argininosuccinate lyase; ADC, arginine decarboxylase; ODC, ornithine decarboxylase; OAT, ornithine aminotransferase; P5C, pyrroline-5-carboxylate; P5CR,
pyrroline-5-carboxylate reductase.
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Arginase I and II have been detected in both vascular SMCs and
ECs but the abundance of each isoform is variable and likely
reflects differences between animal species, vascular beds, size and
function of blood vessels, and/or culture conditions. Table 1 illus-
trates the regulation of arginase expression and activity in SMCs
and ECs derived from various animal species in response to specific
biochemical and biophysical stimuli. Rat aortic SMCs possess sub-
stantial arginase activity that is associated with the selective expres-
sion of arginase I (Durante et al., 1997, 2001; Wei et al., 2000). This
contrasts with results obtained in human pulmonary artery SMCs
where both isoforms are expressed (Chen et al., 2009). Several
inducers of arginase have been identified in vascular SMCs. Our
laboratory identified growth factors and cyclic mechanical strain
as potent inducers of arginase I in rat aortic SMCs. Moreover, we
showed that growth factors and hemodynamic forces stimulate the
uptake of l-arginine and inhibit the expression of iNOS by vas-
cular SMCs (Durante et al., 1996a, 1997, 2000). These coordinate
actions of growth factors are synchronized to promote the prolif-
erative capacity of SMCs by directing l-arginine metabolism from
the formation of NO to l-ornithine, the first step in polyamine syn-
thesis. Alternatively, the actions of cyclic strain are orchestrated to
increase collagen synthesis by channeling l-arginine transport and
metabolism to the production of l-proline. The combination of
interleukin-13 (IL-13) and interleukin-4 also stimulates arginases I
expression in rat aortic SMCs (Wei et al., 2000) while IL-13 induces
the expression of arginase II via the IL-13 receptor α2 (IL-13Rα2)
in human pulmonary artery SMCs (Cho et al., 2013). In addi-
tion, hypoxia selectively increases arginase II expression in SMCs
isolated from human pulmonary arteries (Chen et al., 2009). The
induction of arginase II by IL-13 or hypoxia contributes to the
proliferation of pulmonary SMCs (Chen et al., 2012; Cho et al.,
2013). Consistent with these in vitro findings, intimal hyperplasia
in premenopausal human uterine arteries is paralleled by an ele-
vation in the expression of both arginase I and II (Loyaga-Rendon
et al., 2005; Marinova et al., 2008). Moreover, arginase activity pos-
itively correlates to the magnitude of intimal thickening in these
blood vessels. Thus, the expression of both isoforms of arginase is
regulated in a dynamic fashion in SMCs by distinct biochemical
and biophysical stimuli to elicit discrete proliferative or fibrotic
responses.
Endothelial dysfunction arising from impaired NO synthesis
is a fundamental feature in many cardiovascular disorders. Con-
sideration of the enzyme kinetics for NOS and arginase indicate
that arginase effectively competes with NOS for l-arginine under
Table 1 | Regulation of cellular arginase expression and activity.
Cell type Species Isoform Inducer or activator Reference
SMC Rat I IL-13/IL-4 Wei et al. (2000)
Rat I TGF-β1 Durante et al. (2001)
Rat I Cyclic strain Durante et al. (2000)
SMC Human II IL-13 Cho et al. (2013)
Human II Hypoxia Chen et al. (2012)
EC Rat I and II LPS Buga et al. (1996)
EC Human I and II LPS and TNFα Bachetti et al. (2004)
EC Cow I and II LPS and TNFα Chicoine et al. (2004)
EC Mouse I TNFα Gao et al. (2007)
EC Human II Hypoxia Toby et al. (2010)
Human II Hypoxia Krotova et al. (2010)
Human II Thrombin Ming et al. (2004)
Human II Thrombin, TRAP Yang et al. (2006)
EC Rat I Thrombin Zhu et al. (2010)
EC Cow I Hydrogen peroxide Chandra et al. (2012)
Cow I Angiotensin II, peroxynitrite Shatanawi et al. (2011)
EC Mouse II Oxidized LDL Ryoo et al. (2011)
EC Pig I Oxidized LDL Wang et al. (2011b)
EC Rat, human I Hyperglycemia, high glucose Romero et al. (2008)
EC Mouse I Hyperglycemia Yao et al. (2013)
EC Pig II Shear stress Thacher et al. (2010)
EC Human I Nitric oxide Santhanam et al. (2007)
EC Pig I and II Uric acid Zharikov et al. (2008)
SMC, smoothmuscle cells; EC, endothelial cells; IL-13, interleukin-13; IL-4, interleukin-4; LPS, lipopolysaccharide;TGF-β1, transforming growth factor-β1;TRAP, thrombin
receptor activating peptide; oxidized LDL, oxidized low-density lipoprotein.
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physiologic conditions (Wu and Morris, 1998), providing a frame-
work by which arginase can provoke endothelial malfunction.
Indeed, arginase has been linked to endothelial dysfunction in an
expanding number of vascular pathologies, including atheroscle-
rosis, hypertension, uremia, aging, diabetes, ischemia-reperfusion,
and hemorrhagic shock (see Durante et al., 2007; Johnson et al.,
2010; Michell et al., 2011). Interestingly, a large number of fac-
tors that trigger endothelial dysfunction are able to stimulate
endothelial arginase activity and/or expression. Several studies
have reported that inflammatory mediators stimulate the expres-
sion of both arginase I and II, and this may be linked to the acti-
vation of the Src family tyrosine kinases in pulmonary ECs (Buga
et al., 1996; Bachetti et al., 2004; Chicoine et al., 2004; Nelin et al.,
2005; Gao et al., 2007; Chang et al., 2008). Hypoxia is also a potent
inducer of arginase II in pulmonary ECs (Krotova et al., 2010; Toby
et al., 2010). The induction of arginase II by hypoxia is likely medi-
ated by hypoxia-inducible factor 2 since silencing this transcrip-
tion factor negates the rise in arginase II expression. Interestingly,
the serine protease thrombin stimulates endothelial arginase activ-
ity via at least two distinct mechanisms (Ming et al., 2004; Yang
et al., 2006; Zhu et al., 2010). While thrombin-mediated increases
in arginase II activity occurs via a Rho pathway, the induction of
arginase I gene expression by thrombin is mediated through acti-
vator protein-1 activation (Ming et al., 2004; Zhu et al., 2010).
The Rho pathway appears to play a central role in mediating the
induction of endothelial arginase expression in response to many
atherogenic stimuli, including angiotensin II, oxidized low-density
lipoprotein, hyperglycemia, hydrogen peroxide, and peroxynitrite
(Thengchaisri et al., 2006; Ryoo et al., 2011; Shatanawi et al., 2011;
Wang et al., 2011b; Chandra et al., 2012; Yao et al., 2013). As
observed in SMCs, hemodynamic forces also regulate arginase
expression in ECs. Exposure of cultured ECs or isolated carotid
arteries to unidirectional shear stress modestly elevates arginase II
expression whereas oscillatory shear stress, a hemodynamic pat-
tern known to favor plaque development, strongly induces the
expression of arginase II, demonstrating that endothelial arginase
expression is highly sensitive to disturbances in fluid flow (Thacher
et al., 2010). Post-translational modes of regulating arginase have
also been reported. In particular, NO release by iNOS stimulates
arginase I activity in ECs by S-nitrosylating a specific cysteine
residue of the protein (Santhanam et al., 2007). This nitrosylation
event stabilizes the arginase I trimer and causes a sixfold increase
in the affinity of the enzyme for l-arginine, allowing it to better
compete with NOS for l-arginine. A direct interaction between
the oxygenase domain of iNOS and arginase I was required for
the nitrosylation of arginase I to occur (Dunn et al., 2011). Simi-
larly, uric acid activates both arginase isoforms by enhancing their
affinity for l-arginine but the underlying mechanism remains
unresolved (Zharikov et al., 2008). Thus, numerous pathologic
stimuli that cause endothelial dysfunction stimulate the expression
and/or activity of arginase in ECs via multiple pathways.
ROLE OF ARGINASE IN VASCULAR REMODELING
ARGINASE IN ARTERIAL INJURY
Considerable evidence indicates that arginase plays an integral
role in neointima formation. Intimal lesions following endothelial
denudation of carotid arteries are larger in diabetic rabbits relative
to normoglycemic animals and they exhibit greater arginase activ-
ity and expression (Ishizaka et al., 2007). In addition, a combined
transcriptomic and proteomic study identified an increase in
arginase I expression in arteriotomy-injured rat carotid arteries
(Forte et al., 2008). Consistent with this investigation, we recently
reported that balloon injury of rat carotid arteries results in a pro-
nounced increase in arginase I protein expression that is coupled
to a sustained increase in arginase activity (Peyton et al., 2009).
Arginase I expression is detected throughout the injured blood
vessel but it is especially prominent in the neointima. Although
arterial injury also induces iNOS synthase expression (Yan et al.,
1996; Tulis et al., 2000), the concomitant elevation in arginase I
compromises NO synthesis at the site of injury (Alef et al., 2011).
The underlying mechanism responsible for inducing arginase I
expression is not known; however, the generation of growth fac-
tors and/or inflammatory cytokines following arterial injury may
be involved.
Balloon injury of rat carotid arteries results in the development
of a concentric SMC-rich neointima. However, local perivas-
cular application of the arginase inhibitors S-(2-boronoethyl)-
l-cysteine or hydroxy-nor-l-arginine immediately after arterial
injury markedly diminishes neointima formation without affect-
ing vessel caliber (Peyton et al., 2009). The inhibition of intimal
hyperplasia is independent of any increase in apoptosis but is asso-
ciated with a significant decline in medial and neointimal DNA
synthesis, suggesting that arginase promotes intimal thickening
by stimulating the proliferation of vascular SMCs. Indeed, trans-
fection of cultured vascular SMCs with arginase I stimulates cell
growth by increasing the production of polyamines while phar-
macological inhibition of arginase suppresses polyamine synthesis
and SMC replication (Wei et al., 2001). We also demonstrated that
arginase promotes the entry of vascular SMCs into the cell cycle
since blocking arginase activity or silencing arginase I expression
arrests cells in the G0/G1 phase of the cell cycle (Peyton et al.,
2009). The cell cycle arrest and blockade of neointimal thicken-
ing following arginase inhibition is associated with a significant
increase in the expression of the cyclin-dependent kinase inhibitor
p21, a known mediator of G1 arrest. The ability of arginase to
suppress polyamine synthesis may contribute to the upregulation
of p21 since polyamines have been demonstrated to repress p21
gene transcription (Liu et al., 2006). In addition, the discovery
that arginase stimulates collagen synthesis by SMCs may further
exacerbate intimal thickening by increasing collagen deposition in
injured blood vessels (Durante et al., 2000, 2001). The prolifera-
tive and fibrotic actions of arginase I are further amplified by the
capacity of arginase I to compete with iNOS for l-arginine and
restrict the generation of NO, which is an established inhibitor of
SMC proliferation and collagen synthesis (Garg and Hassid, 1989;
Kolpakov et al., 1995).
ARGINASE IN PULMONARY AND ARTERIAL HYPERTENSION
Vascular remodeling is a seminal feature in pulmonary arterial
hypertension (PAH) that leads to increased pulmonary vascular
resistance and reduced compliance. It is characterized by the pro-
nounced thickening of blood vessels and marked by increases in
the proliferation of pulmonary artery SMCs and ECs, the exten-
sion of SMCs into smaller, non-muscular pulmonary arteries
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within the respiratory sinus (neovascularization), and enhanced
deposition of extracellular matrix, including collagen (Humbert
et al., 2004). EC dysfunction is also observed in PAH and this can
further compromise pulmonary blood flow and lead to throm-
bosis. Recent work suggests that arginase contributes to vascular
remodeling in PAH. Both isoforms of arginase are expressed in
the lungs of mice exposed to chronic hypoxia but only elevated
levels of arginase II are detected in pulmonary arterial ECs of
patients with PAH (Xu et al., 2004; Jin et al., 2010). The induc-
tion of arginase activity in the pulmonary circulation is paralleled
by the development of EC dysfunction and decreases in NO syn-
thesis, suggesting competition between arginase and eNOS for
l-arginine (Xu et al., 2004; Sasaki et al., 2007). Increased expres-
sion of arginase II is also observed in the pulmonary vasculature
of a novel genetic model of PAH in which IL-13 is specifically
overexpressed in the lung (Cho et al., 2013). These transgenic
mice spontaneously develop PAH with obvious vascular remodel-
ing exemplified by lung fibrosis, prominent medial thickening of
pulmonary arteries, and neovascularization of small pulmonary
arteries. While the expression of both arginase isoforms is found
in alveolar macrophages, only arginase II expression is noted
in vascular SMCs and ECs. Interestingly, deletion of arginase
II decreases medial wall thickening of pulmonary arteries and
reduces the frequency of neovascularization of small pulmonary
arteries in IL-13 overexpressing transgenic mice, demonstrating
that arginase II contributes to pathologic vascular remodeling in
these animals.
Arginase II drives arterial thickening in PAH by stimulating
the proliferation of vascular SMCs. Treatment of human pul-
monary artery SMCs with IL-13 induces the expression of arginase
II and this is associated with a marked increase in cell growth
(Cho et al., 2013). Moreover, knocking down arginase II blocks
the IL-13-mediated increase in SMC proliferation. Similarly, pul-
monary SMCs exposed to hypoxia exhibit increases in arginase
II mRNA and protein expression (Chen et al., 2009). Arginase
inhibition with S-(2-boronoethyl)-l-cysteine or molecular silenc-
ing of arginase II expression completely prevents hypoxia-induced
SMC proliferation. Since enhanced endothelial arginase II expres-
sion is associated with prominent intimal thickening in human
PAH patients (Xu et al., 2004), arginase II may also contribute to
the growth of ECs in this disorder. In support of this proposal,
transfection of bovine coronary ECs with arginase II increases cell
proliferation in a manner that is strictly dependent on polyamine
synthesis (Li et al., 2002). In addition, hypoxia-induced prolif-
eration of human pulmonary microvascular ECs is blocked by
arginase inhibition (Toby et al., 2010). Thus, the ability of arginase
II to stimulate the proliferation of both SMCs and ECs may play
an essential role in propelling the obstructive remodeling response
observed in PAH. Furthermore, arginase-mediated increases in
collagen accumulation may contribute to the development of pul-
monary arterial stiffness and fibrosis in PAH (Kobs and Chesler,
2006).
Arginase also influences vascular remodeling in arterial hyper-
tension. Arginase activity is elevated in a number of animal
models of essential or secondary hypertension. We previously
reported that skeletal muscle arterioles from salt-loaded, salt-
sensitive hypertensive rats express higher levels of arginase I and
II, and that endothelial dysfunction in this vascular bed is cor-
rected by arginase inhibition (Johnson et al., 2005). Restoration of
EC function following arginase inhibition has also been described
in deoxycorticosterone acetate-salt hypertensive rats, renovascu-
lar hypertensive pigs, and spontaneously hypertensive rats (SHR)
(Rodriguez et al., 2000; Zhang et al., 2004; Demougeot et al., 2005;
Johnson et al., 2005). In addition, upregulation of arginase activity
contributes to attenuation of cutaneous vasodilation in hyperten-
sive patients (Holowatz and Kenney, 2007). Aside from improving
endothelial function, arginase inhibitors prevent the development
of hypertension when given to pre-hypertensive or young adult
SHR (Bagnost et al., 2008). More recently, chronic pharmacolog-
ical inhibition of arginase was also found to sustainably reduce
blood pressure in fully developed hypertensive SHR (Bagnost
et al., 2010). Notably, arginase inhibition prevents remodeling of
the aorta in these animals. There is a significant decline in aor-
tic medial wall thickness, aortic media to lumen ratio, and type
I collagen content in SHR treated with hydroxy-nor-l-arginine.
In addition, arginase inhibition dramatically increases the arterial
compliance of carotid arteries in SHR. However, arginase inhi-
bition has no effect on the remodeling of mesenteric arteries,
suggesting that arginase-mediated vascular remodeling is vessel
dependent in these animals. The ability of arginase inhibition
to repress aortic remodeling and arterial stiffness likely occurs
due to decreases in SMC proliferation and collagen synthesis, and
improvements in EC function. Interestingly, arginase I is selec-
tively induced in the vasculature of SHRs suggesting that arginase I,
rather than arginase II, mediates hypertensive vascular remodeling
in conduit arteries of the systemic circulation.
ARGINASE IN AGING
Aging is associated with changes in arterial wall structure and func-
tion. The most frequent modifications are luminal enlargement,
vessel wall thickening due to intimal and medial expansion, elastin
depletion and fragmentation, collagen and calcium deposition,
glycation of proteins, and impaired vasomotor function associated
with endothelial dysfunction (Virmani et al., 1991; Taddei et al.,
2001; Mirea et al., 2012). These structural and functional alter-
ations in aging contribute to increased vascular stiffness, which is
an independent risk factor for cardiovascular morbidity and mor-
tality (Sutton-Tyrrell et al., 2005; Dolan et al., 2006; Mattace-Raso
et al., 2006). Accumulating evidence indicates that arginase con-
tributes to aging-associated EC dysfunction and arterial stiffening.
In aged rats, the upregulation of iNOS activity in blood vessels
induces the S-nitrosylation and activation of arginase I (San-
thanam et al., 2007). Although arginase-mediated depletion of l-
arginine reduces NO synthesis, the tight physical coupling between
iNOS and arginase I is likely sufficient to sustain S-nitrosylation
and activation of arginase I (Dunn et al., 2011). Importantly,
arginase inhibition restores NO synthesis and reverses endothe-
lial dysfunction and vascular stiffness in old rats (Kim et al.,
2009). Recent findings also support a role for arginase in mediat-
ing endothelial dysfunction in the circulation of aged human skin
(Holowatz et al., 2006). Interestingly, increased arginase II activ-
ity contributes to endothelial dysfunction in aged mice, indicating
that distinct isoforms of arginase are activated and provoke EC
dysfunction in different animal species of aging (Shin et al., 2012).
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ARGINASE IN ATHEROSCLEROSIS
Emerging evidence indicates that arginase also contributes to
the development of atherosclerotic lesions. Endothelial arginase
II activity is significantly increased in apolipoprotein E (apoE)-
deficient hypercholesterolemic mice or in wild-type animals fed a
high cholesterol diet in the absence of any increase in arginase II
expression (Ryoo et al., 2008). Strikingly, pharmacological block-
ade of arginase reduces plaque burden by approximately 50%
and markedly reduces average wall thickness of the ascending
aorta in apoE-deficient animals. In addition, arginase inhibition
improves arterial compliance in apoE-null mice to levels seen
in wild-type animals. Similarly, deletion of arginase II in apoE-
deficient mice fed either a high fat or high cholesterol diet results
in smaller arterial lesions. In addition, the size of necrotic cores
in advanced lesions is substantially reduced in arginase II-apoE
double knockout mice despite comparable levels of circulating
cholesterol and triglycerides (Ming et al., 2012). In contrast,
apoE-deficient transgenic mice with EC-specific overexpression
of arginase II exhibit increased aortic lesion development without
a change in plasma lipids (Vaisman et al., 2012). Together, these
animal studies demonstrate that elevations in endothelial arginase
II activity or expression contributes to arterial stiffness and the
development of atherosclerotic lesions that possess a vulnerable
phenotype, independent of any alteration in the lipid profile.
There are several potential mechanisms by which arginase II
exerts its atherogenic effect. Since impaired endothelial dysfunc-
tion and NO release plays an important role in the development
and progression of atherosclerosis (Lerman and Zeiher, 2005), the
ability of arginase to evoke endothelial dysfunction is highly sig-
nificant. Endothelial function and NO synthesis are compromised
in apoE-deficient mice but arginase inhibition or arginase II gene
deletion restores NO production and endothelial function in these
animals (Ryoo et al., 2008). Importantly, arginase inhibition has
recently been demonstrated to acutely improve endothelial func-
tion in patients with coronary artery disease (Shemyakin et al.,
2012). The beneficial effect of arginase inhibitors in these subjects
is completely dependent on the increased bioavailability of NO.
In-line with these findings, endothelial overexpression of arginase
II induces endothelial dysfunction and hypertension in mice, fur-
ther underscoring the detrimental nature of this enzyme in the
cardiovascular system (Vaisman et al., 2012).
Arginase II may also promote atherogenesis by augment-
ing the inflammatory response of leukocytes. Monocytes and
macrophages are key cellular protagonists of atherosclerosis that
play a fundamental role in the initiation, progression, and rup-
ture of atherosclerotic plaques (Libby, 2002; Mantovani et al.,
2009; Shibata and Glass, 2009). Monocytes readily infiltrate vas-
cular lesions, differentiate into macrophages, ingest lipoprotein
particles, and give rise to foam cells. Macrophages are major cel-
lular contributors to the lesion’s physical bulk and contribute to
the evolution of the plaque by secreting inflammatory cytokines
and reactive oxygen species. They also weaken and destabilize
plaque by releasing various proteases. However, monocytes and
macrophages are phenotypically diverse and can express pro- and
anti-atherogenic programs. Interestingly, recent work suggests that
arginase influences the polarization of these cells. In particu-
lar, the expression of arginase II is coupled with the classically
activated M1 macrophage phenotype, which fosters the release
of inflammatory mediators and proteases, and is associated with
advanced atherosclerotic lesions (Khallou-Laschet et al., 2010;
Ming et al., 2012). In addition, silencing arginase II expression in
human monocytes suppresses their pro-inflammatory function:
both monocyte adhesion onto activated ECs and inflammatory
cytokine production is blocked. The pro-inflammatory role of
arginase II is also observed in vivo. Targeted disruption of arginase
II blunts the infiltration of macrophages into various organs and
the expression of inflammatory cytokines in adipose tissue of
mice fed a high fat diet (Ming et al., 2012). Arginase II defi-
ciency also limits macrophage content and cytokine expression
in atherosclerotic plaques of apoE-null mice. Moreover, adoptive
transfer experiments reveals that fewer donor arginase II-deficient
monocytes than arginase II-competent macrophages infiltrate into
the plaque of apoE-depleted mice, while apoE-arginase II double
knockout mice accumulate fewer monocytes than do recipient
single knockout apoE animals. Thus, arginase II may exacerbate
arterial lesion formation by promoting both endothelial dys-
function and the pro-inflammatory potential of monocytes and
macrophages.
Surprisingly, an atheroprotective role for arginase I has
been identified in macrophages. Using subtractive suppression
hybridization to screen for differentially expressed genes in
macrophages obtained from two strains of rabbits with geneti-
cally determined high and low predisposition to atherosclerosis,
arginase I is found to be expressed at higher levels in macrophages
with low atherosclerotic response relative to those with a high
response (Teupser et al., 2006). Consistent with these findings,
a marked reduction in arginase I gene expression is noted in
foam cell macrophages compared with non-foamy macrophages in
cholesterol-fed rabbits (Thomas et al., 2007). Immunohistochem-
istry reveals arginase I expression in superficial and adventitial
macrophages and by foam cells and SMCs underlying the fibrous
cap with reduced expression deeper within the plaque of advanced
rabbit lesions. In human carotid atherosclerotic plaques, arginase
I is also widely distributed in the superficial cell layers but is absent
from macrophages close to or within the lipid core. The expression
of arginase I by macrophages is associated with the alternatively
activated M2 macrophage which promotes resolution of inflam-
mation by releasing anti-inflammatory cytokines and engulfing
cellular debris (Martinez et al., 2009). Thus, arginase I may resolve
inflammatory reactions within atherosclerotic lesions by regulat-
ing macrophage polarization. In support of this notion, mRNA
expression profiling experiments found that macrophages from
regressing murine plaques display enhanced levels of arginase
I (Feig et al., 2012). Furthermore, arginase I expression modu-
lates the inflammatory response of vascular SMCs. Overexpression
of arginase I inhibits cytokine production and the activation of
the pro-inflammatory transcription factor, nuclear factor-κB, by
SMCs (Wang et al., 2011a). In addition, intraplaque gene delivery
of arginase I reduces macrophage infiltration and inflammation in
arterial lesions of rabbits while local silencing of arginase I expres-
sion aggravates these responses. Aside from attenuating inflam-
mation, the expression of arginase I in SMCs near the fibrous cap
of atherosclerotic lesions may also promote plaque stability by
stimulating SMC proliferation.
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MODEL FOR THE REGULATION OF VASCULAR REMODELING BY
ARGINASE
Recent studies implicate arginase as a critical contributor to the
structural and functional remodeling of arteries that underlies a
number of vascular diseases. Figure 2 presents a model where
arginase plays a central role in vessel wall remodeling in response
to arterial injury, PAH, arterial hypertension, and aging. All four
of these pathologic states stimulate the activity and/or expres-
sion arginase I or II in blood vessels, while arterial injury and
aging also induces the expression of iNOS. The induction of iNOS
by aging or arterial injury may further augment the activation
of arginase I by nitrosylating a specific cysteine residue of the
enzyme. Activation and/or induction of both arginase isoforms
stimulate SMC and EC proliferation, and/or collagen synthesis
by increasing the production of polyamines and l-proline. These
cellular actions of arginase are further amplified by the abil-
ity of arginase to limit the metabolism of l-arginine by iNOS
and eNOS to NO, which is a known inhibitor of SMC prolifer-
ation and collagen synthesis. Collectively, these arginase-driven
events result in neointima formation, medial wall thickening,
neovascularization of small arteries, vasoconstriction, and/or arte-
rial stiffness. Emerging work indicates that arginase also con-
tributes to arterial remodeling in atherosclerosis; however, the role
played by the two arginase isoforms appears to differ (Figure 3).
The induction of arginase II activity in atherosclerosis stimu-
lates plaque development and vulnerability, and vascular stiffness
by triggering EC dysfunction and the inflammatory potential of
macrophages. In contrast, the induction of arginase I expression
promotes plaque stability by blocking the inflammatory responses
of macrophages and SMCs, and by stimulating the proliferation
of vascular SMCs.
THERAPEUTIC STRATEGIES TARGETING ARGINASE IN
VASCULAR REMODELING
Several approaches can be employed to target arginase in vascu-
lar remodeling. One promising approach involves the develop-
ment and use of pharmacological inhibitors. While early attempts
to establish a role for arginase were hampered by the lack
of potent and specific inhibitors of arginase, recent develop-
ment of boronic acid and N-hydroxy-guanidinium derivatives,
such as 2(S)-amino-6-boronohexanoic acid, S-(2-boronoethyl)-
l-cysteine and N G-hydroxy-nor-l-arginine, has yielded highly
potent competitive inhibitors that can readily be used to probe
arginase function (Christianson, 2005). The effectiveness of these
arginase inhibitors has been demonstrated in various in vitro
and in vivo models, including humans (see Durante et al., 2007;
Holowatz and Kenney, 2007; Morris, 2009; Shemyakin et al.,
2012). However, further pharmacokinetic and toxicology stud-
ies are needed in order to optimize safe and effective therapeutic
regimens for these inhibitors. One important limitation with cur-
rently available pharmacological inhibitors is their inability to
provide isoform-selective inhibition of arginase. The development
of small molecule inhibitors that discriminate between arginase I
and II will be critical when targeting vascular disorders in which
different arginase isoforms elicit disparate actions in blood ves-
sels. Some concern has also been raised over possible non-specific
actions of certain arginase inhibitors (Huynh et al., 2009). Given
FIGURE 2 | Model for the regulation of vascular remodeling by arginase
in arterial injury, pulmonary arterial hypertension (PAH), arterial
hypertension, and aging. Arterial injury, PAH, arterial hypertension, and
aging stimulates the activity and/or expression of arginase I or II in blood
vessels, while arterial injury and aging also stimulates the expression of
inducible nitric oxide (NO) synthase (iNOS). The induction of iNOS by aging
or arterial injury may further augment the activation of arginase I by
nitrosylating a specific cysteine residue of the enzyme. Activation or
induction of both arginase isoforms stimulate vascular smooth muscle cell
(SMC) and endothelial cell (EC) proliferation, and collagen synthesis by
increasing the production of polyamines and L-proline. These cellular
actions of arginase are further amplified by the ability of arginase to limit
the metabolism of L-arginine by iNOS and endothelial NO synthase (eNOS)
to NO, which is a known inhibitor of SMC proliferation and collagen
synthesis. Collectively, these arginase-driven events result in neointima
formation, medial wall thickening, neovascularization of small arteries,
vasoconstriction, and/or arterial stiffness.
the paucity of isoform-selective arginase inhibitors, small inter-
ference RNA (siRNA) has been extensively employed to silence
arginase I and II expression in cultured vascular cells. In addition,
siRNA has been successfully used to knock down arginase expres-
sion in blood vessels both ex vivo and in vivo (Wang et al., 2011a;
Shin et al., 2012). Although siRNA technology holds great promise,
current difficulties in delivery, and potential safety and off-target
effects limit the clinical efficacy of this approach (Keaney et al.,
2011).
Another potential strategy in blocking arginase activity involves
the use of dietary antioxidants. Cocoa flavanols lower arginase II
mRNA expression and activity in cultured human ECs while oral
ingestion of flavanols decreases arginase activity in rat kidney and
in human erythrocytes (Schnorr et al., 2008). The catechin, epi-
catechin gallate, improves scar formation during incisional wound
healing in rats and this is associated with a decrease in arginase
I expression and activity (Kapoor et al., 2004). In addition, the
intake of red wine polyphenols ameliorates endothelial dysfunc-
tion and arginase I expression in blood vessels of middle-aged rats
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FIGURE 3 | Model for the regulation of atherosclerotic plaque
progression and stability by arginase. The induction of arginase II activity in
atherosclerosis stimulates plaque development and vulnerability by
stimulating endothelial cell (EC) dysfunction, the inflammatory potential of
macrophages, and arterial stiffness. In contrast, the induction of arginase I
expression in atherosclerosis promotes plaque stability by blocking the
inflammatory responses of macrophages and vascular smooth muscle cells
(SMCs) and stimulating the proliferation of vascular SMCs.
(Dal-Ros et al., 2012). Furthermore, the bioflavonoid, quercetin,
suppresses liver arginase activity in acute renal failure (Nikolic
et al., 2003). Interestingly, Danshen, a traditional Chinese herbal
medicine that is commonly used for the prevention and treat-
ment of cardiovascular disease, may exert its beneficial vascular
effects, in part, through the inhibition of arginase (Joe et al.,
2012). Consequently, a variety of dietary approaches may be
used in limiting arginase activation; however, detailed clinical
studies are needed to establish the efficacy of any nutritional
approach.
There is a growing awareness that clinically relevant drugs
are able to suppress arginase activity. This is best exemplified
by the statin family of drugs which lower circulating choles-
terol levels by inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl-
CoA reductase. Several statins are capable of inhibiting arginase
activity. Daily treatment of diabetic rats with simvastatin blunts
diabetes-induced endothelial dysfunction and arginase I expres-
sion (Romero et al., 2008). In addition, lovastatin and sim-
vastatin completely block the induction of arginase II activ-
ity by oxidized low-density lipoprotein in human ECs (Ryoo
et al., 2011). Furthermore, in an acute murine model of allergic
asthma, simvastatin represses arginase I protein expression and
early hallmarks of airway remodeling (Zeki et al., 2010). More-
over, oral atorvastatin therapy restores cutaneous microvascular
function by decreasing arginase activity in hypercholesterolemic
humans (Holowatz et al., 2011), indicating that arginase inhibi-
tion contributes to the pleiotropic and anti-atherogenic actions of
statins. The mechanism by which statins reduce arginase activ-
ity likely occurs through inhibition of RhoA and Rho-kinase
signaling (Ryoo et al., 2011). Aside from statins, the angiotensin-
converting enzyme inhibitor, lisinopril, reverses the elevation
in arginase activity in erythrocytes from patients with ather-
osclerosis and hypertension while the phosphodiesterase type
3 inhibitor, cilostamide, inhibits hypoxia-induced arginase II
expression in human pulmonary artery SMCs (Chen et al., 2012;
Kosenko et al., 2012). Furthermore, oral administration of 17β-
estradiol in oophorectomized rabbits fed a cholesterol enriched
diet decreases atheromatous lesions and this is accompanied
by reductions in both arginase I and II expression, illustrating
a potential hormonal approach in targeting arginase (Hayashi
et al., 2006). Thus, an increasing number of drugs used in the
treatment of cardiovascular disease have been shown to inhibit
arginase expression and/or activity, and some evidence sug-
gests that arginase inhibition contributes to their therapeutic
efficacy.
CONCLUSION
Recent experimental studies have implicated arginase as a key
contributor to the detrimental vascular remodeling response
observed in arterial injury, pulmonary and arterial hypertension,
aging, and atherosclerosis. The application of potent pharma-
cological inhibitors of arginase has provided important novel
insight into the role of arginase in regulating vascular cell func-
tion. In addition, they have proven effective in improving vas-
cular remodeling in animal models of arterial disease and rep-
resent an attractive near-term clinical strategy. Interestingly, sev-
eral natural occurring antioxidants have been demonstrated to
block arginase activity and/or expression, providing a potential
dietary approach in targeting the enzyme. Given the differen-
tial expression of arginase I and II between discrete vascular
cells and blood vessels, and their divergent actions in certain
pathological settings, the development of potent isoform-selective
arginase inhibitors is highly desirable. While molecular approaches
using siRNA to silence arginase expression are promising, fur-
ther refinements in this technology are needed to permit the
clinical targeting of distinct arginase isoforms. Future transla-
tional studies will determine the success any of these strategies
in treating or preventing obstructive fibroproliferative vascular
disease.
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